{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "sole-discretion", "type": "clause", "offset": [40, 55]}, {"key": "notice-to", "type": "definition", "offset": [88, 97]}, {"key": "in-writing", "type": "definition", "offset": [104, 114]}, {"key": "in-advance", "type": "clause", "offset": [140, 150]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [176, 208]}, {"key": "in-the-territory", "type": "clause", "offset": [209, 225]}], "samples": [{"hash": "3gmdlwghpQt", "uri": "/contracts/3gmdlwghpQt#target-launch-date", "label": "Co Promotion Agreement (Tyme Technologies, Inc.)", "score": 31.3874053955, "published": true}, {"hash": "friqgxPJJMM", "uri": "/contracts/friqgxPJJMM#target-launch-date", "label": "Co Promotion Agreement (Eagle Pharmaceuticals, Inc.)", "score": 31.3572902679, "published": true}, {"hash": "6YVaaJ6hgnx", "uri": "/contracts/6YVaaJ6hgnx#target-launch-date", "label": "Co Promotion Agreement (Eagle Pharmaceuticals, Inc.)", "score": 31.1656398773, "published": true}], "size": 5, "snippet": "means the date selected by TYME, in its sole discretion, and of which TYME has provided notice to Eagle in writing at least nine (9) months in advance thereof, for the initial Commercialization of the Product in the Territory.", "hash": "eb568d90f33adaff3d97a83a2e76106b", "id": 1}, {"snippet_links": [{"key": "in-the-case", "type": "clause", "offset": [28, 39]}, {"key": "hong-kong", "type": "clause", "offset": [98, 107]}], "samples": [{"hash": "4Q2AvNlEnnX", "uri": "/contracts/4Q2AvNlEnnX#target-launch-date", "label": "License and Supply Agreement (Omp Inc)", "score": 18.0, "published": true}, {"hash": "3sl35K3IrJd", "uri": "/contracts/3sl35K3IrJd#target-launch-date", "label": "License and Supply Agreement (Omp Inc)", "score": 18.0, "published": true}], "size": 2, "snippet": "means (a) December 31, 1999 in the case of Taiwan and (b) June 30, 2000 in the case of Singapore, Hong Kong and Japan.", "hash": "a983e49b90fea821717de99960b60cc5", "id": 2}, {"snippet_links": [], "samples": [{"hash": "a5m2upIeIW", "uri": "/contracts/a5m2upIeIW#target-launch-date", "label": "Manufacturing, Publishing and Distribution Agreement (Mad Catz Interactive Inc)", "score": 26.7960300446, "published": true}], "size": 1, "snippet": "has the meaning set forth in Section 4.3.2.", "hash": "19a449319ae6719583eb6d9ac6f7d4d1", "id": 3}, {"snippet_links": [], "samples": [{"hash": "2pqFvHhoUVp", "uri": "/contracts/2pqFvHhoUVp#target-launch-date", "label": "Cooperation and Development Agreement (Net2phone Inc)", "score": 18.0, "published": true}], "size": 1, "snippet": "means [****].", "hash": "1e83f8111f883b0fd2a42bcdc6f1004f", "id": 4}, {"snippet_links": [{"key": "target-date", "type": "definition", "offset": [10, 21]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [38, 70]}, {"key": "in-the-territory", "type": "clause", "offset": [71, 87]}, {"key": "sole-discretion", "type": "clause", "offset": [132, 147]}, {"key": "provided-that", "type": "definition", "offset": [149, 162]}, {"key": "notice-of", "type": "clause", "offset": [240, 249]}, {"key": "in-writing", "type": "definition", "offset": [273, 283]}, {"key": "prescription-drug-user-fee-act", "type": "clause", "offset": [341, 371]}, {"key": "submitted-by", "type": "definition", "offset": [389, 401]}, {"key": "accepted-for-filing", "type": "definition", "offset": [409, 428]}], "samples": [{"hash": "jy3fh3E8V6I", "uri": "/contracts/jy3fh3E8V6I#target-launch-date", "label": "Co Promotion Agreement (G1 Therapeutics, Inc.)", "score": 31.5927448273, "published": true}], "size": 1, "snippet": "means the target date for the initial Commercialization of the Product in the Territory, which date shall be selected by G1, in its sole discretion; provided that (a) such target date shall be no earlier than [***] and (b) G1 shall provide notice of such target date to BI in writing no later than [***] following G1\u2019s receipt from FDA of a Prescription Drug User Fee Act date for the NDA submitted by G1 and accepted for filing by FDA.", "hash": "36da645199d9beecf0d4754658ed563b", "id": 5}, {"snippet_links": [{"key": "in-clause", "type": "clause", "offset": [0, 9]}, {"key": "replaced-with", "type": "clause", "offset": [56, 69]}, {"key": "agreement-of-the-parties", "type": "clause", "offset": [155, 179]}, {"key": "in-writing", "type": "definition", "offset": [180, 190]}], "samples": [{"hash": "eOlyrg6Ga4x", "uri": "/contracts/eOlyrg6Ga4x#target-launch-date", "label": "Supply and License Agreement (HedgePath Pharmaceuticals, Inc.)", "score": 29.0273780823, "published": true}], "size": 1, "snippet": "in Clause 1.1 of the Existing SLA is hereby deleted and replaced with the following: \u201cTarget Launch Date is June 30, 2020, as that date may be extended by agreement of the parties in writing.\u201d", "hash": "b30d10ea08b80f10b79e7730a057bf37", "id": 6}, {"snippet_links": [], "samples": [{"hash": "6oizdMP9tmB", "uri": "/contracts/6oizdMP9tmB#target-launch-date", "label": "License Agreement (Cme Group Inc.)", "score": 21.0, "published": true}], "size": 1, "snippet": "has the meaning set forth in Schedule A.", "hash": "e2eeb269b74e5ee9efbed418451f9c48", "id": 7}, {"snippet_links": [{"key": "section-81", "type": "clause", "offset": [14, 25]}], "samples": [{"hash": "laf8gf0eXiq", "uri": "/contracts/laf8gf0eXiq#target-launch-date", "label": "Etf Master Agreement", "score": 27.238193512, "published": true}], "size": 1, "snippet": "is defined in Section 8.1 and Paragraph J1. Licenciantes e que podem, no total, compor um \u00cdndice S&P.", "hash": "bf97b15ec5a6cf9e7e7651705f0661fe", "id": 8}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [6, 21]}, {"key": "roll-out-plan", "type": "definition", "offset": [69, 82]}], "samples": [{"hash": "9q0tNhMsZoc", "uri": "/contracts/9q0tNhMsZoc#target-launch-date", "label": "Marketplace Agreement (E Centives Inc)", "score": 18.0, "published": true}], "size": 1, "snippet": "means with respect to each country the date specified as such in the Roll Out Plan.", "hash": "30e1d8eaf77379b794ebaec75a2bb716", "id": 9}, {"snippet_links": [{"key": "the-start-date", "type": "definition", "offset": [31, 45]}], "samples": [{"hash": "jPfqLpYnK0C", "uri": "/contracts/jPfqLpYnK0C#target-launch-date", "label": "Supplemental Agreement to the Supply Contract (Sunday Communications LTD)", "score": 21.0, "published": true}], "size": 1, "snippet": "means six (6) months following the Start Date.", "hash": "c3c8b00f6f803f936cb555cda402f49b", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbdGFyZ2V0LWxhdW5jaC1kYXRlIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 18, "title": "Target Launch Date", "snippet": "means the date selected by TYME, in its sole discretion, and of which TYME has provided notice to Eagle in writing at least nine (9) months in advance thereof, for the initial Commercialization of the Product in the Territory.", "id": "target-launch-date", "examples": ["If, notwithstanding HPPI\u2019s compliance with clause 5.1, a Marketing Authorisation has not been obtained by HPPI, any Affiliate or Sub Licensee at least *** before the <strong>Target Launch Date</strong>, then following consultation with the other party for up to ***, either party, acting reasonably, may terminate this agreement with immediate effect with notice to the other party.", "Following the acceptance of the NDA for SM-88 (racemetyrosine) by the FDA and no later than 90 days prior to the <strong>Target Launch Date</strong>, TYME shall use Commercially Reasonable Efforts to cause sufficient quantities of Product to be available in inventory to promptly fill orders throughout the Territory and otherwise meet the forecasted demand for Product in the Territory.", "For the avoidance of doubt, such guidelines and procedures shall provide that any Eagle Sales Representative, Field Force Personnel or Eagle Affiliate that becomes aware of an Adverse Event shall follow all TYME policies and procedures regarding Adverse Event reporting, including TYME\u2019s Adverse Event Reporting standard operating procedure, which shall be provided to Eagle for training prior to the <strong>Target Launch Date</strong>.", "Subject to the terms of this Agreement, no later than six (6) months prior to the <strong>Target Launch Date</strong>, TYME and Eagle (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall identify and finalize the responsibilities the Parties shall employ to protect patients and promote their well-being in a separate safety data exchange agreement (\u201cPharmacovigilance Agreement\u201d).", "In the event that TYME incurs costs and expenses for which Eagle is responsible under this Section 4.4.1, TYME may deduct such amounts from the payments due under Section 6.1 and shall include a description thereof in the applicable report under Section 6.2. The Parties shall collaborate to finalize the Product Materials in accordance with this Section 4.4.1(a) in advance of the <strong>Target Launch Date</strong>.", "Prior to the <strong>Target Launch Date</strong>, Eagle shall develop an incentive compensation package for each Sales Representative that derives an appropriate portion of target incentive compensation from achieving target sales of the Product, subject to TYME\u2019s review and comment prior to implementation of the incentive plan.", "Licensee shall procure a ground image receive station and image processing center that shall be operational and capable of receiving and processing OrbView-3 System imagery data no later than the <strong>Target Launch Date</strong>.", "Eagle shall have such sales force in place by such time specified in the Operating Parameters Schedule in order to appropriately train on the Product prior to <strong>Target Launch Date</strong>.", "In the event that the OrbView-3 System satellite has not been launched within six months of the <strong>Target Launch Date</strong>, then ORBIMAGE and Licensee shall each have the option to terminate the Agreement immediately, provided that written notice of termination must be delivered to the other party no later than May 15, 1999 (or the first business day thereafter if May 15 falls on a weekend).", "Such credit shall only be applicable on any royalty payment date so long as, on such royalty payment date, (i) Obagi has not breached any material provision of this Agreement in any material respect, (ii) Obagi shall have met or exceeded the minimum order requirements for all prior periods, and (iii) except to the extent delayed by applicable laws or regulatory authorities, Obagi shall have launched in Taiwan, Singapore, Hong Kong and Japan not later than the <strong>Target Launch Date</strong> therefor."], "related": [["launch-date", "Launch Date", "Launch Date"], ["launch", "Launch", "Launch"], ["milestone-date", "Milestone Date", "Milestone Date"], ["commercial-launch", "Commercial Launch", "Commercial Launch"], ["milestone-dates", "Milestone Dates", "Milestone Dates"]], "related_snippets": [], "updated": "2025-07-26T06:21:18+00:00"}, "json": true, "cursor": ""}}